Researcher Profile

Researcher Profile

Salah Almokadem, MD

Salah Almokadem, MD

Assistant Professor, Department of Medicine
Division of Hematology and Oncology
Disease Teams:
Head and Neck Cancer
Thoracic Cancer
sma11@psu.edu

Research Interests

  • Therapeutics
  • Neoplasms
  • volociximab
  • Squamous Cell Carcinoma of Head and Neck
  • Non-Small Cell Lung Carcinoma
  • Pharmacokinetics
  • Integrins
  • Safety
  • Clinical Trials
  • Survival
  • Squamous Cell Carcinoma
  • Allergy and Immunology

Clinical Trials

APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC)(KEYNOTE-867) MK 3475-867
A Phase III Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK7339-013)
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (MRT849-001)
A Phase II, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)
NRG-HN005 - A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Phase II, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
An Open-Label, Multicenter, Phase I/II Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
A Phase II Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) CX-839-014
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
S1827 A randomized Phase III trial comparing prophylactic cranial irradiation (PCI) for any patient with small cell lung cancer (either extensive or limited stage) to active surveillance with MRI in place of PCI
A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-396
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
Oncogenic Mutations/Gene Rearrangements in Patients with Advanced Adenocarcinoma Lung
Characterization of Oncogenic Mutations in Patients with Advanced Squamous Cell Lung Cancer
Oncogenic Driver Mutations/Biomarkers in Screening Participants for Early Detection of Lung Cancer
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
Tissue and Blood Collection from Patients with Suspected Lung Cancer

Recent Publications

2019

KEYNOTE-040 investigators 2019, 'Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study', The Lancet, vol. 393, no. 10167, pp. 156-167. https://doi.org/10.1016/S0140-6736(18)31999-8

2017

Liu, J, Goldenberg, D, Almokadem, S, Crist, H & Mackley, HB 2017, 'Long-term recurrence-free survival after an unplanned reduction in radiotherapy for HPV-positive oropharyngeal SCC: Two cases and a review of the literature', Ear, Nose and Throat Journal, vol. 96, no. 7, E23. https://doi.org/10.1177/014556131709600705
Stoller, R, Schmitz, JC, Ding, F, Puhalla, S, Belani, CP, Appleman, L, Lin, Y, Jiang, Y, Almokadem, S, Petro, D, Holleran, J, Kiesel, BF, Ken Czambel, R, Carneiro, BA, Kontopodis, E, Hershberger, PA, Rachid, M, Chen, A, Chu, E & Beumer, JH 2017, 'Phase I study of veliparib in combination with gemcitabine', Cancer Chemotherapy and Pharmacology, vol. 80, no. 3, pp. 631-643. https://doi.org/10.1007/s00280-017-3409-3

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)